



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number (Optional)

In re Application of: **Donald B. Borders et al.**

Application No.: 10/810,741-Conf. #9685

Filed: March 26, 2004

For: **EXTRACTIVE PURIFICATION OF LIPOPEPTIDE ANTIBIOTICS**

The owner*, Migenix Inc., of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of **prior patents** No. **6,716,962** and **6,511,962** as the term of said prior patent is defined in 35 U.S.C. 154 and 173, and as the term of said **prior patents** is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the **prior patents** are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the **prior patents**, "as the term of said **prior patents** is presently shortened by any terminal disclaimer," in the event that said **prior patents** later:

expire for failure to pay a maintenance fee;
are held unenforceable;
are found invalid by a court of competent jurisdiction;
are statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
have all claims canceled by a reexamination certificate;
are reissued; or
are in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 46,985

Signature

February 28, 2006
Date

Jeffrey C. Pepe, Ph.D.
Typed or printed name

(206) 262-8911
Telephone Number

- ☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

03/03/2006 AKELECH1 00000021 040100 10810741

02 FC:2814	65.00 DA
------------	----------

STATEMENT UNDER 37 CFR 3.73(b) - Supplemental Sheet

Continuation of chain of title from the inventor(s) to the current assignee.

4. From: Micrologix Biotech Inc. To: Migenix Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 016662 , Frame 0582 , or for which a copy thereof is attached.